NewLimit
NewLimit is seeking a Scientist to establish and grow its mRNA analytical testing suite, leading the development of analytical methods to characterize DNA templates and mRNAs. This hands-on, lab-based role within Technical Operations will interface with Delivery Sciences, research teams, and external CDMOs to support process development efforts as programs advance toward the clinic. The position involves building the analytical suite from the ground up, running and maintaining assays, and collaborating on documentation and method transfers.
Headquarters
South San Francisco, California, United States
Company Size
11-50 employees
Founded
2022
NewLimit is a biotechnology company focused on extending human healthspan by unlocking regenerative potential. It builds therapies and platform technologies aimed at restoring youthful function to tissues and organs by targeting core cellular and molecular drivers of aging. NewLimit advances programs through preclinical research and collaborations to translate regenerative biology into treatments for age‑related disease. The company emphasizes translational science with the goal of delivering durable, clinically meaningful rejuvenation across organ systems.
Anti-aging biotech NewLimit brings in Eli Lilly as investor, raising $45M
Oct 20, 2025
Anti-aging biotech NewLimit raises $130M to push liver reprogramming med into clinic
May 6, 2025
NewLimit ‘close’ to clinic-ready epigenetic reprogramming therapy
Nov 27, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for NewLimit.
88% above the average for this role
NewLimit Raises $45 Million Funding to Advance Longevity Research
Oct 21, 2025